Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|March 28, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
- Volume 10
- Issue 4
AmerisourceBergen Acquires Minority Interest in Profarma
Author(s)Melanie Sena
AmerisourceBergen to establish a joint venture for specialty distribution with Profarma.
Advertisement
AmerisourceBergen
reported that it has reached a definitive agreement to acquire a minority stake in Profarma, a pharmaceutical wholesaler in Brazil. In addition, AmerisourceBergen and Profarma will establish a joint venture for specialty distribution and services. The company expects to invest a total of approximately $100 million, and the transaction is expected to close in the June quarter of 2014.
AmerisourceBergen will purchase up to a 19.9% minority stake by offering $22.50 per share for shares offered in a primary offering by Profarma. This distribution joint venture will include Profarma’s existing specialty businesses and an equity investment from AmerisourceBergen. As a result, each company will own a 50% stake in the joint venture.
Source:
AmerisourceBergen
Articles in this issue
over 12 years ago
Pharma Industry Corruption in China Under Scrutinyover 12 years ago
Western CMOs Rise Again, Face New Challengesover 12 years ago
How Will CMO Ownership Changes Impact Market?over 12 years ago
Covance Expands Global Biologics Capabilitiesover 12 years ago
Vetter Implements New Serialization Servicesover 12 years ago
Catalent Increases Investment in Redwood BioscienceAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Germany’s Medical Biotechnology Sector is Flourishing
5